4.2 Post-Exposure Management Protocols
Key Takeaways
Immediate post-exposure management for bloodborne pathogen exposure requires washing needle sticks and wounds with soap and water and flushing mucous membranes with water or saline for 15 minutes.
HIV post-exposure prophylaxis (PEP) consists of a 3-drug antiretroviral regimen that should be initiated as soon as possible, ideally within 2 hours of exposure, and continued for 28 days.
Hepatitis B post-exposure prophylaxis depends on source HBsAg status and employee vaccine response; unvaccinated or non-responder employees exposed to HBsAg-positive blood require HBIG and HBV vaccination.
Routine PEP is not recommended for Hepatitis C exposures; management relies on baseline testing and follow-up HCV RNA testing at 3–6 weeks, with direct-acting antivirals initiated if infection develops.
Non-bloodborne post-exposure management includes macrolide prophylaxis for pertussis, post-exposure MMR/varicella vaccination or immune globulin for measles/varicella, and two-step post-exposure testing for tuberculosis.
Post-Exposure Management Protocols
Occupational exposures to bloodborne pathogens (BBP) and communicable infectious diseases represent high-priority medical emergencies in healthcare facilities. Infection preventionists, occupational health providers, and clinical supervisors must execute immediate, standardized management protocols to minimize transmission risks following an exposure.
Exposure Definition & Immediate First Aid
An occupational exposure is defined as a percutaneous injury (e.g., needlestick or cut with a contaminated sharp instrument), contact of mucous membranes (eyes, nose, mouth), or contact of non-intact skin (dermatitis, chapped, abraded skin) with blood, tissue, or potentially infectious body fluids.
Infectious vs. Non-Infectious Body Fluids
- Potentially Infectious for BBP: Blood, semen, vaginal secretions, cerebrospinal fluid (CSF), synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, and amniotic fluid.
- Non-Infectious for BBP (unless visibly bloody): Tears, sweat, urine, feces, saliva, vomitus, and nasal secretions.
Immediate First Aid Measures
- Percutaneous Injuries & Skin Cuts: Wash the wound thoroughly with soap and water immediately. Do NOT squeeze or milk the wound, and do NOT apply harsh caustic antiseptics (such as bleach or concentrated iodine) into the wound.
- Mucous Membrane Splashes: Flush the affected eyes, nose, or mouth with copious amounts of clean water or sterile saline for at least 15 minutes.
- Reporting: Report the exposure incident immediately to occupational health or the emergency department supervisor.
Source Patient Evaluation
Immediate efforts must be made to identify and evaluate the source patient:
- Obtain informed consent (per state law) and rapidly test source patient blood for:
- HIV: 4th-generation HIV antigen/antibody immunoassay.
- Hepatitis B: Hepatitis B surface antigen (HBsAg).
- Hepatitis C: Hepatitis C virus antibody (anti-HCV) with reflex HCV RNA.
- Critical Clinical Rule: Post-exposure prophylaxis (PEP) for the exposed employee must never be delayed while awaiting laboratory results from the source patient.
Bloodborne Pathogen PEP Algorithms
1. Human Immunodeficiency Virus (HIV) PEP
- Indications: Significant percutaneous or mucous membrane exposure to blood or infectious fluids from a known HIV-positive source or a high-risk unknown source.
- Standard 3-Drug PEP Regimen: Preferred combination includes 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI):
- Tenofovir disoproxil fumarate (TDF) + Emtricitabine (FTC) once daily, PLUS
- Raltegravir twice daily OR Dolutegravir once daily.
- Timing & Duration: PEP must be initiated as soon as possible, ideally within 2 hours post-exposure. Efficacy drops significantly if delayed beyond 72 hours. Total duration of treatment is 28 days.
- Follow-up Testing Schedule: Baseline HIV testing, followed by repeat testing at 6 weeks and 4 months post-exposure (or 12 weeks post-exposure if using a 4th-generation Ag/Ab combination assay).
2. Hepatitis B Virus (HBV) PEP Protocol
Post-exposure management for HBV depends on the source patient's HBsAg status and the exposed employee's vaccination and anti-HBs response status:
| Exposed Employee Status | Source HBsAg Positive | Source HBsAg Negative | Source Unknown / Untested |
|---|---|---|---|
| Vaccinated Responder (anti-HBs ) | No treatment required | No treatment required | No treatment required |
| Vaccinated Non-Responder (anti-HBs after 2 series) | Administer 2 doses HBIG (1 mo apart) OR 1 dose HBIG + re-vaccination | No treatment required | Treat as if source is positive if high-risk source |
| Unvaccinated / Incomplete Series | Administer 1 dose HBIG () immediately + initiate HBV vaccine series | Complete HBV vaccine series | Complete HBV vaccine series |
| Vaccinated, Unknown Response | Test anti-HBs immediately. If , no PEP. If , give 1 dose HBIG + vaccine booster | No treatment required | Test anti-HBs. If , administer vaccine booster |
Note: HBIG should be administered as soon as possible, ideally within 24 hours post-exposure (maximum window: 7 days).
3. Hepatitis C Virus (HCV) Management Protocol
- PEP Recommendation: No post-exposure prophylaxis is recommended for HCV exposure. Neither immune globulin nor direct-acting antiviral (DAA) medications are approved for immediate post-exposure prophylaxis.
- Baseline & Follow-up Testing:
- Baseline testing of exposed employee: anti-HCV antibody, HCV RNA, and baseline ALT.
- Early detection monitoring: Perform HCV RNA testing at 3 to 6 weeks post-exposure.
- Confirmation testing: Perform anti-HCV testing at 4 to 6 months post-exposure (with reflex HCV RNA if positive).
- Treatment Protocol: If acute HCV infection is confirmed (positive HCV RNA), refer the employee to a specialist for Direct-Acting Antiviral (DAA) therapy. DAA therapy yields cure rates (sustained virologic response) .
Non-Bloodborne Pathogen Post-Exposure Protocols
Occupational health must manage exposures to airborne, droplet, and contact pathogens effectively:
| Pathogen / Disease | PEP / Prophylactic Intervention | Timing of Intervention | Work Restriction Window |
|---|---|---|---|
| Tuberculosis (TB) | Baseline IGRA/TST; repeat IGRA/TST at 8–10 weeks post-exposure | Baseline immediately; repeat at 8–10 wk | No restriction unless active TB disease suspected |
| Varicella (VZV) | Varicella vaccine (healthy non-immune) or VARIZIG (high-risk/pregnant) | Vaccine within 3–5 days; VARIZIG within 96 hr (up to 10 days) | Exclude non-immune HCP from day 8 to day 21 post-exposure |
| Measles (Rubeola) | MMR vaccine (non-immune) | Administer within 72 hours post-exposure | Exclude non-immune HCP from day 5 to day 21 post-exposure |
| Pertussis | Oral Azithromycin ( day 1, days 2–5) regardless of Tdap status | Initiate as soon as exposure identified | Restrict symptomatic HCP until 5 days of antibiotics completed |
| Scabies | Topical Permethrin 5% cream applied neck down overnight | Apply single treatment immediately | Restrict from care until 24 hours after treatment applied |
A phlebotomist sustains a deep percutaneous needle stick from a needle contaminated with blood from a known HIV-positive patient with a high viral load. What is the recommended timeline for initiating HIV post-exposure prophylaxis (PEP) and the duration of treatment?
Initiate PEP within 24 hours and continue treatment for 14 days
Initiate PEP as soon as possible, ideally within 2 hours, and continue treatment for 28 days
Initiate PEP within 72 hours and continue treatment until follow-up HIV testing at 6 weeks
Initiate PEP only if the employee exhibits symptoms of acute retroviral syndrome within 7 days
An unvaccinated environmental services worker sustains a hollow-bore needlestick injury from a source patient who tests positive for Hepatitis B surface antigen (HBsAg). What post-exposure prophylaxis is required for this employee?
No post-exposure prophylaxis is indicated; observe for clinical symptoms of acute hepatitis
Administer a single dose of Hepatitis B vaccine within 7 days of exposure
Administer Hepatitis B Immune Globulin (HBIG) immediately and initiate the 3-dose Hepatitis B vaccine series
Administer two doses of Hepatitis B Immune Globulin (HBIG) 1 month apart without vaccination
A nurse is exposed to blood from a patient with active chronic Hepatitis C virus (HCV) infection via a deep scalpel wound. What is the correct post-exposure management strategy for this nurse?
Administer immune globulin (IG) immediately and initiate a 28-day course of ribavirin
Administer a single dose of direct-acting antiviral (DAA) therapy within 48 hours post-exposure
Perform baseline anti-HCV testing and re-test anti-HCV at 12 months; no lab work is needed prior to 12 months
Perform baseline HCV antibody and RNA testing, perform follow-up HCV RNA testing at 3–6 weeks, and treat if infection occurs
An intensive care unit nurse is exposed to an infant with laboratory-confirmed pertussis without wearing a mask. The nurse received a Tdap booster 2 years ago. What post-exposure management is recommended?
Provide a 5-day course of post-exposure antimicrobial prophylaxis with oral azithromycin regardless of Tdap status
Administer an immediate repeat dose of Tdap vaccine and restrict the nurse from patient care for 14 days
No post-exposure prophylaxis or restriction is required because the nurse received Tdap within the last 5 years
Obtain a nasopharyngeal swab for PCR and withhold antimicrobial prophylaxis unless symptoms develop
Sections you finish are checked off in the contents.